Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moessner

Showing results (341-350 of 361) with videos related to

Pageof 37
Sort By:
Nature Communications|November 18, 2024
Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumorsMacarena Román Alonso, Ariadna Grinyó-Escuer, Santiago Duro-Sánchez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2016
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid TumorsMarina Bacac, Tanja Fauti, Johannes Sam, et al.
Haematologica|April 3, 2016
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapyMarie-Luise Hütter-Krönke, Axel Benner, Konstanze Döhner, et al.
Archives of General Psychiatry|July 8, 2009
Genome-wide association study of alcohol dependenceJens Treutlein, Sven Cichon, Monika Ridinger, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|May 12, 2021
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressantsC B Eap, G Gründer, P Baumann, et al.
Oncoimmunology|April 14, 2017
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokinesChristian Klein, Inja Waldhauer, Valeria G Nicolini, et al.
Mabs|May 11, 2021
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapyInja Waldhauer, Valeria Gonzalez-Nicolini, Anne Freimoser-Grundschober, et al.
American Journal of Human Genetics|February 7, 2008
Structural variation of chromosomes in autism spectrum disorderChristian R Marshall, Abdul Noor, John B Vincent, et al.
Current Sports Medicine Reports|March 11, 2015
Ice Hockey Summit II: zero tolerance for head hits and fightingAynsley M Smith, Michael J Stuart, David W Dodick, et al.
Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine|April 14, 2015
Ice Hockey Summit II: zero tolerance for head hits and fightingAynsley M Smith, Michael J Stuart, David W Dodick, et al.
Pageof 37

Showing results (341-350 of 361) with videos related to

Sort By:
Pageof 37
Nature Communications|November 18, 2024
Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumorsMacarena Román Alonso, Ariadna Grinyó-Escuer, Santiago Duro-Sánchez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2016
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid TumorsMarina Bacac, Tanja Fauti, Johannes Sam, et al.
Haematologica|April 3, 2016
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapyMarie-Luise Hütter-Krönke, Axel Benner, Konstanze Döhner, et al.
Archives of General Psychiatry|July 8, 2009
Genome-wide association study of alcohol dependenceJens Treutlein, Sven Cichon, Monika Ridinger, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|May 12, 2021
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressantsC B Eap, G Gründer, P Baumann, et al.
Oncoimmunology|April 14, 2017
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokinesChristian Klein, Inja Waldhauer, Valeria G Nicolini, et al.
Mabs|May 11, 2021
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapyInja Waldhauer, Valeria Gonzalez-Nicolini, Anne Freimoser-Grundschober, et al.
American Journal of Human Genetics|February 7, 2008
Structural variation of chromosomes in autism spectrum disorderChristian R Marshall, Abdul Noor, John B Vincent, et al.
Current Sports Medicine Reports|March 11, 2015
Ice Hockey Summit II: zero tolerance for head hits and fightingAynsley M Smith, Michael J Stuart, David W Dodick, et al.
Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine|April 14, 2015
Ice Hockey Summit II: zero tolerance for head hits and fightingAynsley M Smith, Michael J Stuart, David W Dodick, et al.
Pageof 37